Black patients with MS or neuromyelitis optica spectrum disorder experienced faster repopulation of B cells 6 to 12 months after rituximab or ocrelizumab infusion compared with white patients, according to preliminary results.
llya Kister, MD, of NYU Grossman School of Medicine in New York and a Fellow of the American Academy of Neurology, and colleagues also found that relative distribution of B-cell subsets — including CD19, CD20 and others — was similar between Black and white patients. The researchers presented their findings at the American Academy of Neurology annual meeting,